Neuropsychiatric Lupus with Antibody-Mediated Striatal Encephalitis

References

1. 1.↵
   2. Borchers AT,
   3. Naguwa SM,
   4. Shoenfeld Y, et al

   . The geoepidemiology of systemic lupus erythematosus. Autoimmun Rev 2010;9:A277–87 doi:10.1016/j.autrev.2009.12.008 pmid:20036343

   CrossRefPubMedWeb of Science
2. 2.↵
   2. Popescu A,
   3. Kao AH

   . Neuropsychiatric systemic lupus erythematosus. Curr Neuropharmacol 2011;9:449–57 doi:10.2174/157015911796557984 pmid:22379459

   CrossRefPubMed
3. 3.↵
   2. Kivity S,
   3. Agmon-Levin N,
   4. Zandman-Goddard G, et al

   . Neuropsychiatric lupus: a mosaic of clinical presentations. BMC Med 2015;13:43 doi:10.1186/s12916-015-0269-8 pmid:25858312

   CrossRefPubMed
4. 4.↵
   2. Gerosa M,
   3. Poletti B,
   4. Pregnolato F, et al

   . Antiglutamate receptor antibodies and cognitive impairment in primary antiphospholipid syndrome and systemic lupus erythematosus. Front Immunol 2016;7:5 doi:10.3389/fimmu.2016.00005 pmid:26870034

   CrossRefPubMed
5. 5.↵
   2. Kowal C,
   3. Degiorgio LA,
   4. Lee JY, et al

   . Human lupus autoantibodies against NMDA receptors mediate cognitive impairment. Proc Natl Acad Sci U S A 2006;103:19854–59 doi:10.1073/pnas.0608397104 pmid:17170137

   Abstract/FREE Full Text
6. 6.↵
   2. Brimberg L,
   3. Mader S,
   4. Fujieda Y, et al

   . Antibodies as mediators of brain pathology. Trends Immunol 2015;36:709–24 doi:10.1016/j.it.2015.09.008 pmid:26494046

   CrossRefPubMed
7. 7.↵
   2. DeGiorgio LA,
   3. Konstantinov KN,
   4. Lee SC, et al

   . A subset of lupus anti-DNA antibodies cross-reacts with the NR2 glutamate receptor in systemic lupus erythematosus. Nat Med 2001;7:1189–93 doi:10.1038/nm1101-1189 pmid:11689882

   CrossRefPubMedWeb of Science
8. 8.↵
   2. Gelb S,
   3. Stock AD,
   4. Anzi S, et al

   . Mechanisms of neuropsychiatric lupus: the relative roles of the blood-cerebrospinal fluid barrier versus blood-brain barrier. J Autoimmun 2018;91:34–44 doi:10.1016/j.jaut.2018.03.001 pmid:29627289

   CrossRefPubMed
9. 9.↵
   2. Küppenbender KD,
   3. Standaert DG,
   4. Feuerstein TJ, et al

   . Expression of NMDA receptor subunit mRNAs in neurochemically identified projection and interneurons in the human striatum. J Comp Neurol 2000;419:407–21 doi:10.1002/(SICI)1096-9861(20000417)419:4<407::AID-CNE1>3.0.CO%3B2-I pmid:10742712

   CrossRefPubMedWeb of Science
10. 10.↵
    2. Dalmau J,
    3. Graus F

    . Antibody-mediated encephalitis. N Engl J Med 2018;378:840–51 doi:10.1056/NEJMra1708712 pmid:29490181

    CrossRefPubMed
11. 11.↵
    2. Dalmau J,
    3. Tüzün E,
    4. Wu HY, et al

    . Paraneoplastic anti-N-methyl-D-aspartate receptor encephalitis associated with ovarian teratoma. Ann Neurol 2007;61:25–36 doi:10.1002/ana.21050 pmid:17262855

    CrossRefPubMedWeb of Science
12. 12.↵
    2. Kelley BP,
    3. Patel SC,
    4. Marin HL, et al

    . Autoimmune encephalitis: pathophysiology and imaging review of an overlooked diagnosis. AJNR Am J Neuroradiol 2017;38:1070–78 doi:10.3174/ajnr.A5086 pmid:28183838

    Abstract/FREE Full Text
13. 13.↵
    2. Dalmau J,
    3. Gleichman AJ,
    4. Hughes EG, et al

    . Anti-NMDA-receptor encephalitis: case series and analysis of the effects of antibodies. Lancet Neurol 2008;7:1091–98 doi:10.1016/S1474-4422(08)70224-2 pmid:18851928

    CrossRefPubMedWeb of Science
14. 14.↵
    2. Luyendijk J,
    3. Steens SC,
    4. Ouwendijk WJ, et al

    . Neuropsychiatric systemic lupus erythematosus: lessons learned from magnetic resonance imaging. Arthritis Rheum 2011;63:722–32 doi:10.1002/art.30157 pmid:21360502

    CrossRefPubMedWeb of Science
15. 15.↵
    2. Rubin DB,
    3. Batra A,
    4. Vaitkevicius H, et al

    . Autoimmune neurologic disorders. Am J Med 2018;131:226–36 doi:10.1016/j.amjmed.2017.10.033 pmid:29126826

    CrossRefPubMed
16. 16.↵
    2. Lee WJ,
    3. Lee ST,
    4. Byun JI, et al

    . Rituximab treatment for autoimmune limbic encephalitis in an institutional cohort. Neurology 2016;86:1683–91 doi:10.1212/WNL.0000000000002635 pmid:27037228

    CrossRefPubMed
17. 17.↵
    2. Lancaster E

    . The diagnosis and treatment of autoimmune encephalitis. J Clin Neurol 2016;12:1–13 doi:10.3988/jcn.2016.12.1.1 pmid:26754777

    CrossRefPubMed
18. 18.↵
    2. Ramos-Casals M,
    3. Soto MJ,
    4. Cuadrado MJ, et al

    . Rituximab in systemic lupus erythematosus: a systematic review of off-label use in 188 cases. Lupus 2009;18:767–76 doi:10.1177/0961203309106174 pmid:19578100

    CrossRefPubMedWeb of Science
19. 19.↵
    2. Tobin WO,
    3. Strand EA,
    4. Clark HM, et al

    . NMDA receptor encephalitis causing reversible caudate changes on MRI and PET imaging. Neurol Clin Pract 2014;4:470–73 doi:10.1212/CPJ.0000000000000074 pmid:25566417

    Abstract/FREE Full Text
20. 20.↵
    2. Graus F,
    3. Titulaer MJ,
    4. Balu R, et al

    . A clinical approach to diagnosis of autoimmune encephalitis. Lancet Neurol 2016;15:391–404 doi:10.1016/S1474-4422(15)00401-9 pmid:26906964

    CrossRefPubMed
21. 21.↵
    2. Dale RC,
    3. Church AJ,
    4. Surtees RA, et al

    . Encephalitis lethargica syndrome: 20 new cases and evidence of basal ganglia autoimmunity. Brain 2004;127:21–33 doi:10.1093/brain/awh008 pmid:14570817

    CrossRefPubMedWeb of Science
22. 22.↵
    2. Brami-Zylberberg F,
    3. Méary E,
    4. Oppenheim C, et al

    . Abnormalities of the basal ganglia and thalami in adults [in French]. J Radiol 2005;86:281–93 doi:10.1016/S0221-0363(05)81357-5 pmid:15908868

    CrossRefPubMed
23. 23.↵
    2. Anderson JC,
    3. Costantino MM,
    4. Stratford T

    . Basal ganglia: anatomy, pathology, and imaging characteristics. Curr Probl Diagn Radiol 2004;33:28–41 doi:10.1016/j.cpradiol.2003.09.004 pmid:14712200

    CrossRefPubMed
24. 24.↵
    2. Menon S,
    3. Jameson-Shortall E,
    4. Newman SP, et al

    . A longitudinal study of anticardiolipin antibody levels and cognitive functioning in systemic lupus erythematosus. Arthritis Rheum 1999;42:735–41 doi:10.1002/1529-0131(199904)42:4<735::AID-ANR17>3.0.CO%3B2-L pmid:10211888

    CrossRefPubMedWeb of Science